Apart from its unclear safety profile in clinical research, we can conclude, based on our dealings with prescribers, that KPV administered subcutaneously can cause certain side effects that are common to most therapeutic peptide injectables: injection site reactions and mild, transient flu-like symptoms
In the last 25 years, several studies have tried to assess whether this could be replaced by oral supplementation
This varies by peptide and goal
Manufactured in a UK Laboratory: Produced under rigorous quality control, adhering to the highest scientific standards
(2019), PMCShort peptides and neuronal differentiation supporting in-vitro context
However, therapies targeting TNF or IL-1 have shown only moderate effectiveness in OA, suggesting the involvement of additional inflammatory pathways